Cargando…

A Synthetic Nanoparticle Based Vaccine Approach Targeting MSP4/5 Is Immunogenic and Induces Moderate Protection Against Murine Blood-Stage Malaria

Malaria remains a significant health problem in many tropical and sub-tropical regions. The development of vaccines against the clinically active blood-stage of infection needs to consider variability and polymorphism in target antigens, and an adjuvant system able to induce broad spectrum immunity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilson, Kirsty L., Pouniotis, Dodie, Hanley, Jennifer, Xiang, Sue D., Ma, Charles, Coppel, Ross L., Plebanski, Magdalena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428706/ https://www.ncbi.nlm.nih.gov/pubmed/30930890 http://dx.doi.org/10.3389/fimmu.2019.00331

Ejemplares similares

Pullulan-Coated Iron Oxide Nanoparticles for Blood-Stage Malaria Vaccine Delivery
por: Powles, Liam, et al.
Publicado: (2020)

Magnetic Nanovectors for the Development of DNA Blood-Stage Malaria Vaccines
por: Al-Deen, Fatin M. Nawwab, et al.
Publicado: (2017)

Comparative Immunogenicity of a Cytotoxic T Cell Epitope Delivered by Penetratin and TAT Cell Penetrating Peptides
por: Brooks, Nicole, et al.
Publicado: (2015)

A Model to Study the Impact of Polymorphism Driven Liver-Stage Immune Evasion by Malaria Parasites, to Help Design Effective Cross-Reactive Vaccines
por: Wilson, Kirsty L., et al.
Publicado: (2016)

Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope
por: Brooks, Nicole, et al.
Publicado: (2018)

The Use of Synthetic Carriers in Malaria Vaccine Design
por: Powles, Liam, et al.
Publicado: (2015)

Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children
por: Sirima, Sodiomon B., et al.
Publicado: (2009)

Correction: Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children
por: Sirima, Sodiomon B., et al.
Publicado: (2010)

Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]
por: Apostolopoulos, Vasso, et al.
Publicado: (2006)

Alveolar Macrophage Polarisation in Lung Cancer
por: Almatroodi, Saleh A., et al.
Publicado: (2014)

Expression of the plasminogen system in the physiological mouse ovary and in the pathological polycystic ovary syndrome (PCOS) state
por: Burchall, Genia F., et al.
Publicado: (2019)

Sperm Protein 17 Expression by Murine Epithelial Ovarian Cancer Cells and Its Impact on Tumor Progression
por: Gao, Qian, et al.
Publicado: (2018)

Montanide, Poly I:C and nanoparticle based vaccines promote differential suppressor and effector cell expansion: a study of induction of CD8 T cells to a minimal Plasmodium berghei epitope
por: Wilson, Kirsty L., et al.
Publicado: (2015)

Functional Recognition by CD8+ T Cells of Epitopes with Amino Acid Variations Outside Known MHC Anchor or T Cell Receptor Recognition Residues
por: Wilson, Kirsty L., et al.
Publicado: (2020)

Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12–24 months
por: Lusingu, John PA, et al.
Publicado: (2009)

Allelic diversity of MSP1 and MSP2 repeat loci correlate with levels of malaria endemicity in Senegal and Nigerian populations
por: Oboh, Mary A., et al.
Publicado: (2021)

A Phase 1 Trial of MSP2-C1, a Blood-Stage Malaria Vaccine Containing 2 Isoforms of MSP2 Formulated with Montanide® ISA 720
por: McCarthy, James S., et al.
Publicado: (2011)

A Nanoparticle Based Sp17 Peptide Vaccine Exposes New Immuno-Dominant and Species Cross-reactive B Cell Epitopes
por: Xiang, Sue D., et al.
Publicado: (2015)

Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8(+) T Cell Responses
por: Xiang, Sue D., et al.
Publicado: (2018)

Production and Immunogenicity of a Tag-Free Recombinant Chimera Based on PfMSP-1 and PfMSP-3 Using Alhydrogel and Dipeptide-Based Hydrogels
por: Anand, Gaurav, et al.
Publicado: (2021)

Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso
por: NEBIE, I, et al.
Publicado: (2009)

Plasmodium falciparum Genetic Diversity in Panamá Based on glurp, msp-1 and msp-2 Genes: Implications for Malaria Elimination in Mesoamerica
por: Santamaría, Ana María, et al.
Publicado: (2020)

Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations
por: Tamborrini, Marco, et al.
Publicado: (2011)

Combined Effects of Gold Nanoparticles and Ionizing Radiation on Human Prostate and Lung Cancer Cell Migration
por: Shahhoseini, Elham, et al.
Publicado: (2019)

Recombinant proteins of Plasmodium malariae merozoite surface protein 1 (PmMSP1): Testing immunogenicity in the BALB/c model and potential use as diagnostic tool
por: Elizardez, Yelina B., et al.
Publicado: (2019)

MSP For Dummies
por: Ferguson, Alan
Publicado: (2014)

Explanting Is an Ex Vivo Model of Renal Epithelial-Mesenchymal Transition
por: Winbanks, Catherine E., et al.
Publicado: (2011)

Safety and Immunogenicity of a Malaria Vaccine, Plasmodium falciparum AMA-1/MSP-1 Chimeric Protein Formulated in Montanide ISA 720 in Healthy Adults
por: Hu, Jinhong, et al.
Publicado: (2008)

Allelic diversity of merozoite surface protein genes (msp1 and msp2) and clinical manifestations of Plasmodium falciparum malaria cases in Aceh, Indonesia
por: Jamil, Kurnia Fitri, et al.
Publicado: (2021)

Cohort study of the association of antibody levels to AMA1, MSP1(19), MSP3 and GLURP with protection from clinical malaria in Ghanaian children
por: Dodoo, Daniel, et al.
Publicado: (2008)

The N-Terminal Region of Plasmodium falciparum MSP10 Is a Target of Protective Antibodies in Malaria and Is Important for PfGAMA/PfMSP10 Interaction
por: Nagaoka, Hikaru, et al.
Publicado: (2019)

Pre-Clinical Assessment of Novel Multivalent MSP3 Malaria Vaccine Constructs
por: Bang, Gilles, et al.
Publicado: (2011)

The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes
por: de Silva, Harini D, et al.
Publicado: (2011)

Evaluation of parasite subpopulations and genetic diversity of the msp1, msp2 and glurp genes during and following artesunate monotherapy treatment of Plasmodium falciparum malaria in Western Cambodia
por: Gosi, Panita, et al.
Publicado: (2013)

The malaria-infected red blood cell: Structural and functional changes
por: Cooke, Brian M., et al.
Publicado: (2001)

Investigation of a novel approach to scoring Giemsa-stained malaria-infected thin blood films
por: Proudfoot, Owen, et al.
Publicado: (2008)

Plasmodium falciparum msp1 and msp2 genetic diversity and allele frequencies in parasites isolated from symptomatic malaria patients in Bobo-Dioulasso, Burkina Faso
por: Somé, Anyirékun Fabrice, et al.
Publicado: (2018)

Genetic diversity of Plasmodium falciparum isolates from patients with uncomplicated and severe malaria based on msp-1 and msp-2 genes in Gublak, North West Ethiopia
por: Mohammed, Hussein, et al.
Publicado: (2019)

Synthetic peptide vaccine confers protection against murine malaria
Publicado: (1987)

Marked variation in MSP-1(19 )antibody responses to malaria in western Kenyan highlands
por: Badu, Kingsley, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_5dikev5e7icp17d592ill0run6